The Health Research Foundation, created by the pharmaceutical industry consortium Innovative Medicines Canada, has created two research chairs at the University of British Colombia and the Northern Ontario School of Medicine. The two posts are dedicated to exploring how to make Canadian health care more resilient to major challenges such as the Covid-19 pandemic.
Organization: Innovative Medicines Canada
The Short Report – August 11, 2021: A feasibility study to export blue hydrogen from Alberta to Asia, tech to reduce pesticide use, and more
Petronas Energy and Itochu Corporation consider exporting blue hydrogen from Alberta, a UWaterloo engineering team gets backing to secure Canada’s critical energy infrastructure, FedNor grows up, and more.
Vaccine independence requires a 21st-Century Connaught Labs, policy experts argue
The federal and Ontario governments recently announced a $470-million investment to expand Sanofi Pasteur Limited’s vaccine manufacturing capability. But for Canada to be truly self-sufficient in vaccine development and production, critics say other models must be considered—including a 21st-century version of Connaught Labs.
Pharma companies urge Ottawa to postpone changes to lower drug prices to next year
Innovative Medicines Canada warns critical research will be impacted if the government forces its members to implement required regulatory changes by July 1.
Québec 2018 Budget: $1B in research and innovation to implement advisory council recommendations, SQRI
Last month, Québec tabled its 2018 budget, which includes more than $1 billion for research, innovation and economic growth, reflecting several recommendations made by the Advisory Council on the Economy and Innovation.
Excerpts: Research ecosystem reacts to Budget 2018
The whole ecosystem is patting themselves on the back, confident that their concerted efforts to lobby behind the Naylor report recommendations — foremost of which was an increase in budget – did not fall on deaf ears. RE$EARCH MONEY offers excerpts of what the ecosystem has to say about the federal budget.
Pharmaceutical R&D spending remains far below industry’s 10% commitment – PMPRB report
Another year of less-than-impressive R&D spending by the pharmaceutical industry has re-ignited the annual sparing match between industry and the organization that compiles the data. The Patented Medicines Prices Review Board (PMPRB) reports that companies belonging to Innovative Medicines Canada (IMC – formerly Rx&D) spent $770 million on R&D in 2016 or 4.9% of its $15.6 billion in sales – a ratio unchanged from 2015.